<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS AND BACKGROUND: The MIAMOD method has been widely applied to derive regional and national <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> burden estimates </plain></SENT>
<SENT sid="1" pm="."><plain>The method is based on a back-calculation approach using <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific mortality and relative survival to derive expected incident and prevalent cases </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0260037" disease_type="Neoplastic Process" abbrv="">Multiple tumors</z:e> occurring in the same site for the same person (for example colon-colon) can be estimated just once </plain></SENT>
<SENT sid="3" pm="."><plain>This has little effect on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific estimates, whereas it limits <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>-combined estimates, where only <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cases, rather than <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnoses, can be accounted for by the method </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of this article is to present a specific strategy of application of the MIAMOD method to <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> sites, which better approximates an estimate of '<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnoses' </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The strategy consists of breaking down the estimation process in separate applications to the most frequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> sites and to a 'remainder-site', given by <z:hpo ids='HP_0000001'>all</z:hpo> malignant sites except the previous ones </plain></SENT>
<SENT sid="6" pm="."><plain>The separate estimates are then summed up to derive the overall quantities for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-specific mortality in the years 1985-2004 in the Tuscany <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry area (about 1,200,000 inhabitants) and relative survival data in the same area and periods (end of follow-up, 31 December 2006) were used to produce the estimates, which were then tested using observed incidence data in the same area and period </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: The standard application of the MIAMOD method underestimates <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence for both sexes </plain></SENT>
<SENT sid="9" pm="."><plain>The mean relative difference between observed and expected incident cases is -14.8% for males and -17.2% for females </plain></SENT>
<SENT sid="10" pm="."><plain>With the alternative method, the same mean relative difference drops to -8.2% for males and -6.1% for females </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The study provides a strategy to reduce a structural limit of the MIAMOD method in estimating the total burden of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> disease </plain></SENT>
</text></document>